(Updating to add stock code of unit and unit's name in headline)
Sihuan Pharmaceutical (HKG:0460) unit Xuanzhu Biopharmaceutical's (HKG:2575) new drug application for a new indication of Anaprazole Sodium Enteric-coated Tablets was accepted by China's National Medical Products Administration.
The acceptance is for the drug to treat adult reflux esophagitis, according to two Tuesday Hong Kong bourse filings by the companies.